CHENGDU OLYMVAX BIOPHARMACEUTICALS financial statements, including revenue, expenses, profit, and loss

The total revenue of 688319 for the last quarter is 159.74 M CNY, and it's 3.54% higher compared to the previous quarter. The net income of Q3 24 is 31.97 M CNY.